Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5782962 | 0.86 | MAPK9 (0.39) | ALDH1A1MAPTLMNAGAASMN1; SMN2 | |
| SCHEMBL30410204 | 0.80 | KMT2A (0.38) | ALDH1A1MAPTHPGDKMT2ASCN9A | |
| SCHEMBL6488894 | 0.78 | MAPT (0.39) | ALDH1A1MAPTLMNAGAASMN1; SMN2 | |
| SCHEMBL14561095 | 0.77 | CES2 (0.43) | ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL1641451 | 0.74 | ALDH1A1 (0.53) | ALDH1A1MAPTLMNASMN1; SMN2HPGD | |
| SCHEMBL27784862 | 0.73 | ACACB (0.42) | ALDH1A1MAPTLMNAGAASMN1; SMN2 | |
| SCHEMBL5771051 | 0.72 | CES1 (0.47) | ALDH1A1MAPTLMNAGAASMN1; SMN2 | |
| SCHEMBL9987173 | 0.71 | LMNA (0.32) | ALDH1A1MAPTLMNASMN1; SMN2HPGD | |
| SCHEMBL1554048 | 0.70 | RAB9A (0.54) | ALDH1A1MAPTLMNAGAASMN1; SMN2 | |
| SCHEMBL1554049 | 0.70 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709468-B2 | Imidazo based heterocycles | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709468-B2 | Imidazo based heterocycles | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709468-B2 | Imidazo based heterocycles | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | disclosed |
| US-7504501-B2 | Antiprotozoal imidazopyridine compounds | MERIAL LIMITED (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1928237-A2 | NOVEL IMIDAZO BASED HETEROCYCLES | Abbott Laboratories (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20070099925-A1 | Novel imidazo based heterocycles | ABBVIE INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070099925-A1 | Novel imidazo based heterocycles | ABBVIE INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070099925-A1 | Novel imidazo based heterocycles | ABBVIE INC. | 2007-05-03 | — | — | US | disclosed |
| US-7196095-B2 | (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds | MERCK & CO., INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196095-B2 | (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds | MERCK & CO., INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20040082604-A1 | Thiazole and imidazo (4,5-B) pyridine compounds and their pharmaceutical use | REVESZ LASZLO (CH) | 2004-04-29 | — | — | US | disclosed |
| US-6608072-B1 | Inhibiting production of soluble tumor necrosis factor or reducing inflammation | NOVARTIS AG (CH) | 2003-08-19 | — | — | US | disclosed |
| EP-1224180-B1 | SUBSTITUTED AZOLES | NOVARTIS AG (CH) | 2003-07-02 | — | — | EP | disclosed |
| US-6579874-B2 | P38 MAP kinase inhibitors; treating Tumor necrosis factor (TNF-alpha) and Interleukin-1 mediated diseases, such as rheumatoid arthritis; imidazole and oxazole derivatives | NOVARTIS AG (CH) | 2003-06-17 | — | — | US | disclosed |
| EP-1224180-A2 | SUBSTITUTED AZOLES | Novartis AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| EP-1224185-A1 | THIAZOLE AND IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Novartis AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| US-20020049220-A1 | Substituted azoles | NOVARTIS AG (CH) | 2002-04-25 | — | — | US | disclosed |
| WO-2001030778-A1 | THIAZOLE AND IMIDAZO [4,5-B] PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | NOVARTIS AG (CH) | 2001-05-03 | — | — | WO | disclosed |
| WO-2000063204-A2 | SUBSTITUTED AZOLES | NOVARTIS AG (CH) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000026209-A1 | ANTI-INFLAMMATORY 4-PHENYL-5-PYRIMIDINYL-IMIDAZOLES | NOVARTIS AG (CH) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099925-A1 | Novel imidazo based heterocycles | CDK4, CDK2, MAP3K19 | ALDH1A1 1071/4885MAPT 4272/4885LMNA 4050/4885 |
| US-20040082604-A1 | Thiazole and imidazo (4,5-B) pyridine compounds and their pharmaceutical use | MAPK1, IRAK1, IRAK4 | ALDH1A1 373/4885MAPT 1385/4885LMNA 3393/4885 |
| US-20020049220-A1 | Substituted azoles | MAPK1, MAPK4, MAP3K1 | ALDH1A1 399/4885MAPT 1214/4885LMNA 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.